Literature DB >> 21169992

Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.

David A Wada1, Mark E Law, Eric D Hsi, David J Dicaudo, Linglei Ma, Megan S Lim, Aieska de Souza, Nneka I Comfere, Roger H Weenig, William R Macon, Lori A Erickson, Nazan Ozsan, Stephen M Ansell, Ahmet Dogan, Andrew L Feldman.   

Abstract

Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides). We previously reported IRF4 (interferon regulatory factor-4) translocations in cutaneous anaplastic large cell lymphomas. Here, we investigated the clinical utility of detecting IRF4 translocations in skin biopsies. We performed fluorescence in situ hybridization (FISH) for IRF4 in 204 biopsies involved by T-cell lymphoproliferative disorders from 182 patients at three institutions. In all, 9 of 45 (20%) cutaneous anaplastic large cell lymphomas and 1 of 32 (3%) cases of lymphomatoid papulosis with informative results demonstrated an IRF4 translocation. Remaining informative cases were negative for a translocation (7 systemic anaplastic large cell lymphomas; 44 cases of mycosis fungoides/Sézary syndrome (13 transformed); 24 peripheral T-cell lymphomas, not otherwise specified; 12 CD4-positive small/medium-sized pleomorphic T-cell lymphomas; 5 extranodal NK/T-cell lymphomas, nasal type; 4 gamma-delta T-cell lymphomas; and 5 other uncommon T-cell lymphoproliferative disorders). Among all cutaneous T-cell lymphoproliferative disorders, FISH for IRF4 had a specificity and positive predictive value for cutaneous anaplastic large cell lymphoma of 99 and 90%, respectively (P=0.00002, Fisher's exact test). Among anaplastic large cell lymphomas, lymphomatoid papulosis, and transformed mycosis fungoides, specificity and positive predictive value were 98 and 90%, respectively (P=0.005). FISH abnormalities other than translocations and IRF4 protein expression were seen in 13 and 65% of cases, respectively, but were nonspecific with regard to T-cell lymphoproliferative disorder subtype. Our findings support the clinical utility of FISH for IRF4 in the differential diagnosis of T-cell lymphoproliferative disorders in skin biopsies, with detection of a translocation favoring cutaneous anaplastic large cell lymphoma. Like all FISH studies, IRF4 testing must be interpreted in the context of morphology, phenotype, and clinical features.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21169992      PMCID: PMC3122134          DOI: 10.1038/modpathol.2010.225

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  20 in total

1.  Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma.

Authors:  S Iida; P H Rao; M Butler; P Corradini; M Boccadoro; B Klein; R S Chaganti; R Dalla-Favera
Journal:  Nat Genet       Date:  1997-10       Impact factor: 38.330

2.  A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells.

Authors:  B Falini; M Fizzotti; A Pucciarini; B Bigerna; T Marafioti; M Gambacorta; R Pacini; C Alunni; L Natali-Tanci; B Ugolini; C Sebastiani; G Cattoretti; S Pileri; R Dalla-Favera; H Stein
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

3.  Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma.

Authors:  Marick E Lae; Iftikhar Ahmed; William R Macon
Journal:  Am J Clin Pathol       Date:  2002-11       Impact factor: 2.493

Review 4.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology.

Authors:  D Benharroch; Z Meguerian-Bedoyan; L Lamant; C Amin; L Brugières; M J Terrier-Lacombe; E Haralambieva; K Pulford; S Pileri; S W Morris; D Y Mason; G Delsol
Journal:  Blood       Date:  1998-03-15       Impact factor: 22.113

5.  Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry.

Authors:  P J Kurtin; K S Hobday; S Ziesmer; B L Caron
Journal:  Am J Clin Pathol       Date:  1999-09       Impact factor: 2.493

6.  CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer Cutaneous Lymphoma Project Group.

Authors:  M Paulli; E Berti; R Rosso; E Boveri; S Kindl; C Klersy; M Lazzarino; G Borroni; F Menestrina; M Santucci
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

8.  The expression of MUM1 in cutaneous T-cell lymphoproliferative disorders.

Authors:  Matthew J Wasco; Douglas Fullen; Lyndon Su; Linglei Ma
Journal:  Hum Pathol       Date:  2008-01-30       Impact factor: 3.466

9.  MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.

Authors:  W Kempf; H Kutzner; A Cozzio; C A Sander; M C Pfaltz; B Müller; M Pfaltz
Journal:  Br J Dermatol       Date:  2008-04-10       Impact factor: 9.302

Review 10.  Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment.

Authors:  R Willemze; R C Beljaards
Journal:  J Am Acad Dermatol       Date:  1993-06       Impact factor: 11.527

View more
  37 in total

1.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

Review 2.  Update: peripheral T-cell lymphomas.

Authors:  Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2011-12       Impact factor: 3.952

Review 3.  ALK-positive anaplastic large cell lymphoma limited to the skin: clinical, histopathological and molecular analysis of 6 pediatric cases. A report from the ALCL99 study.

Authors:  Ilske Oschlies; Jasmin Lisfeld; Laurence Lamant; Atsuko Nakazawa; Emanuele S G d'Amore; Ulrika Hansson; Konnie Hebeda; Ingrid Simonitsch-Klupp; Jadwiga Maldyk; Leonhard Müllauer; Marianne Tinguely; Markus Stücker; Marie-Cecile Ledeley; Reiner Siebert; Alfred Reiter; Laurence Brugières; Wolfram Klapper; Wilhelm Woessmann
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

4.  Morphologic Features of ALK-negative Anaplastic Large Cell Lymphomas With DUSP22 Rearrangements.

Authors:  Rebecca L King; Linda N Dao; Ellen D McPhail; Elaine S Jaffe; Jonathan Said; Steven H Swerdlow; Christopher A Sattler; Rhett P Ketterling; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; Sarah E Gibson; Sarah L Ondrejka; Alina Nicolae; William R Macon; Surendra Dasari; Edgardo Parrilla Castellar; Andrew L Feldman
Journal:  Am J Surg Pathol       Date:  2016-01       Impact factor: 6.394

5.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 6.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

7.  Expression of p63 protein in anaplastic large cell lymphoma: implications for genetic subtyping.

Authors:  Xueju Wang; Rebecca L Boddicker; Surendra Dasari; Jagmohan S Sidhu; Marshall E Kadin; William R Macon; Stephen M Ansell; Rhett P Ketterling; Karen L Rech; Andrew L Feldman
Journal:  Hum Pathol       Date:  2017-01-30       Impact factor: 3.466

8.  Genetic subtyping of breast implant-associated anaplastic large cell lymphoma.

Authors:  Naoki Oishi; Garry S Brody; Rhett P Ketterling; David S Viswanatha; Rong He; Surendra Dasari; Ming Mai; Hailey K Benson; Christopher A Sattler; Rebecca L Boddicker; Ellen D McPhail; N Nora Bennani; Christin A Harless; Kuldeep Singh; Mark W Clemens; L Jeffrey Medeiros; Roberto N Miranda; Andrew L Feldman
Journal:  Blood       Date:  2018-06-19       Impact factor: 22.113

9.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

Review 10.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.